Inactive Instrument

Endo Health Solutions Inc Stock Nasdaq

Equities

US29264F2056

Pharmaceuticals

End-of-day quote Nasdaq
- USD - Intraday chart for Endo Health Solutions Inc
Sales 2022 2.32B Sales 2023 2.01B Capitalization 118K
Net income 2022 -2.92B Net income 2023 -2.45B EV / Sales 2022 2.97 x
Net Debt 2022 6.87B Net Debt 2023 7.41B EV / Sales 2023 3.68 x
P/E ratio 2022
-0.01 x
P/E ratio 2023
-
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 99.35%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 50 14-12-31
Director of Finance/CFO 54 06-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 78 14-01-31
Director/Board Member 77 14-02-27
Director/Board Member 54 21-02-16
More insiders
Endo International plc is a specialty pharmaceutical company. The Company operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL and EDEX, among others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The Company’s Generic Pharmaceuticals segment consists of a product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays.
More about the company